Origin, Occurrence, and Dietary Intake
======================================

The presence of bioactive compounds in fermented beverages has long been observed and they have been studied with great interest. A large body of research has focused on polyphenols, in particular, since these bioactive compounds are already present in plants and released into fermented products. Yeast also transforms certain other molecules into biologically active compounds. Among these, the case of amino acid tryptophan is of interest, since it is the precursor of at least three biologically active compounds: melatonin, serotonin, and tryptophol ([@B62]).

Tryptophol is an alcohol produced by the Ehrlich pathway and it has long been detected in appreciable concentrations in wines and beers in the mg/L range ([@B6]; [@B69]). Therefore, its occurrence in beverages is widely recognized. Moreover, tryptophol has also been indicated as a quorum sensing molecule for yeast ([@B89]).

Just a few years ago, melatonin was detected in wines in much lower levels: within the ng/L range. Not only was it evidenced in wines, but also in other fermented foods, as summarized in **Table [1](#T1){ref-type="table"}**. Furthermore, [@B82] highlighted that melatonin was produced after alcoholic fermentation, pinpointing the role *Saccharomyces* plays. Indeed, different strains synthetized melatonin at different levels ([@B83]).

###### 

Concentration of melatonin and other tryptophan metabolites in fermented products.

  Compound                                                                                                                                Concentration                       Reference
  ------------ -------------------------------------------------------------------------------------------------------------------------- --------------- ------------------- -----------
               **Food**                                                                                                                                                       
  Melatonin    Probiotic yogurt                                                                                                           126.7 ± 9.00    pg/g or pg/mL       [@B51]
               Kefir (fermented milk drink)                                                                                               n.d             pg/g or pg/mL       
               Black olive (naturally fermented)                                                                                          5.3 ± 0.10      pg/g or pg/mL       
               Bread (crumb)                                                                                                              341.7 ± 29.30   pg/g or pg/mL       
               Bread (crust)                                                                                                              138.1 ± 23.20   pg/g or pg/mL       
               Beer                                                                                                                       94.5 ± 6.70     pg/g or pg/mL       
               **Wine**                                                                                                                                                       
               Alaban, Sangiovese, Trebbiano (Italy)                                                                                      0.6-0.4         ng/mL               [@B68]
               Chardonnay, Malbec, Cabernet Sauvignon (Argentina)                                                                         0.16-0.32                           [@B90]
               Gropello, Merlot (Italy)                                                                                                   8.1-5.2                             [@B91]
               Cabernet Saivignon, Merlot, Syrah, Tempranillo, Tintilla de Rota, Petit Verdot, Prieto Picudo, and Palomino fino (Spain)   5.1-420                             [@B82]
               Fermented orange beverage                                                                                                  20.0 ± 2.02     ng/mL               [@B22]
               Red wine                                                                                                                   4.88-9.15       mg/L                [@B69]
               Fermented lentils                                                                                                          2.70+0.25       mg/g dry material   [@B6]
  Tryptophol   Whole-wheat bread                                                                                                          \-                                  [@B46]
               Beer                                                                                                                       0.242 ± 0.200   mg/L                [@B6]
  Serotonin    Beer                                                                                                                       3.5-24.2        mg/L                [@B50]
               Wine                                                                                                                       2.94-5.93       mg/L                [@B93]
                                                                                                                                          1.93 ± 0.043    mg/L                [@B61]
                                                                                                                                          5.5             ng/mL               [@B60]

The synthetic pathway of melatonin in yeast is not completely elucidated, yet it seems the formation of serotonin might be an intermediate in the pathway ([@B62]). In addition, serotonin has been detected at mg/L levels in red wine following malolactic fermentation ([@B93]). Further research is required to explore the roles of yeast and bacteria in the occurrence of these bioactive compounds in fermented products.

One of the characteristics of bioactive compounds is the minimal concentration required for them to act. The reported concentrations in wine and beer would mean that someone consuming these beverages would obtain a low daily intake of these compounds. According to WHO, the daily intake of ethanol should not exceed 30 g and 20 g for men and women, respectively. That is to say that daily intake for a man of a wine can provide up to 0.00005--0.13 mg of melatonin. In a comprehensive review summarizing the results of human intervention studies, [@B35] concluded that the bioavailability of melatonin was 15%. In our example, its bioavailable concentration should result in 1.5--4000 pg/mL of melatonin in blood. Physiological values for day plasma melatonin are very low, accounting for several pg/mL (5--10 pg/mL in human plasma) ([@B17]). Thus, pg/mL in plasma might be expected after dietetic intake of wine or beer, considering the values displayed in **Table [1](#T1){ref-type="table"}**. Indeed, [@B59] determined an increase in the concentration of plasmatic melatonin after the ingestion of a moderate dose of beer (330 mL for women volunteers, 660 mL for men). To the best of our knowledge, there is no published data on the bioavailability of serotonin after food or beverage intake.

Biological Effects and Prevention of Chronic Diseases
=====================================================

Literature on the biological effects of these compounds is extensive and encompasses circadian rhythm, antioxidant properties, and reproductive function. Due to the length of this mini-review, we will focus on more recent findings on the prevention of the most prevalent degenerative diseases, such as cancer, and cardiovascular and neurodegenerative diseases.

Implications for Cancer and Cardiovascular Disease: The Role of Angiogenesis
============================================================================

Angiogenesis, which consists of the formation of new blood vessels from pre-existing ones, is crucial for organ growth during embryonic development and after birth. However, in adulthood, angiogenesis plays an essential role in the pathogenesis of diverse chronic diseases, such as cancer and cardiovascular disease, involving the progression and development of the tumor, and development and destabilization of atherosclerotic plaques ([@B12]; [@B8]).

Angiogenesis occurs when there is an imbalance between pro-angiogenic (e.g., vascular endothelial growth factor (VEGF), basic fibroblast growth factor, alfa tumor necrotic factor, etc.) and anti-angiogenic (e.g., angiostatin and endostatin) factors. VEGF is the most active endogenous pro-angiogenic factor in humans ([@B30]; [@B18]; [@B11]; [@B13]). It exerts its angiogenic effect by stimulating VEGF receptor 2 (VEGFR-2), which is critical for promoting the proliferation and differentiation of endothelial cells ([@B30]; [@B23]). It has been demonstrated that VEGF promotes atherosclerotic plaque progression ([@B12]; [@B49]) and tumor angiogenesis ([@B84]). Indeed, VEGF is a target for drug therapies that aim to inhibit VEGF signaling ([@B23]). Anti-VEGF antibodies, aptamers and small molecule VEGFR tyrosine kinase inhibitors have been developed and given regulatory approval for the treatment of colon, lung, breast, kidney, and liver cancer, in addition to neovascular age-related macular degeneration ([@B30]; [@B23]). However, serious side effects, such as hypertension, have been reported with prolonged use of anti-VEGF therapies ([@B98]; [@B94]; [@B48]). The use of natural products in reducing VEGF-induced angiogenesis may prove to be more beneficial than the current anti-VEGF drugs available ([@B73]).

Melatonin has been associated with a decline in VEGF secretion levels in the serum of advanced cancer patients ([@B57]), in addition to markedly reducing the expression of VEGF in HUVEC and culture cancer cells at 1 μM and 1 mM ([@B16]; [@B15]; [@B5]; [@B31]). Melatonin has also been proven to reduce endothelial cell proliferation, invasion, migration, and tube formation, through downregulation of VEGF at 1 mM ([@B5]). The possible cell signaling pathway when melatonin inhibits HUVEC proliferation has been related to the following pathway: melatonin receptors/ERK/PI3K/Akt/PKC/NF-kB ([@B14]). Additionally, [@B86] have recently demonstrated that melatonin (1 mM) upregulates miRNA3195 and miRNA374b, whose overexpression synergistically reduced VEGF production in hypoxic PC-3 prostate cancer cells, indicating the important role of miRNA3195 and miRNA374b in melatonin induced antiangiogenic activity. Melatonin (40 mg/kg) has also shown an antitumor effect on mammary tumor growth in mice after 21 days of treatment; the mice displayed significantly smaller tumor volume and tumor regression ([@B43]). Additionally, in the same study, a lower expression of VEGFR2 was observed in the melatonin-treated tumors compared to the vehicle-treated tumors. More research is consequently needed to focus on determining the molecular mechanism by which melatonin exerts its angiogenic effect and the molecular target involved.

Neurodegenerative Diseases
==========================

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common human neurodegenerative diseases. In both cases, their incidence increases with age. The aggregation of proteins that results in different fibrillar structures is responsible for these disorders. Specifically, they are owing to the abnormal pathological assembly of amyloid- beta (Aβ), tau and α- synuclein (αS).

Indeed, several studies have demonstrated that protofibrils and oligomers of αS and Aβ are more neurotoxic than fibrils ([@B79]; [@B54]; [@B92]; [@B75]).

This review focus on the evidence of certain bioactives which can present in fermented products. However, to give a fair balance, alcohol effects on neurodegeneration have to be highlighted as it is a major component formed by yeast in alcoholic beverages. It is well-Known that alcohol intake crosses the BBB (Blood--Brain Barrier) easily producing the excessive release of neurotransmitters, oxidative stress and inflammatory response which turns out in neurotoxicity and finally cell death. ([@B78]).

Alzheimer's Disease
===================

Alzheimer's disease is a progressive and irreversible neurodegenerative disorder characterized by loss of memory and cognition, abstract thinking, and personality alteration. The etiology of AD is unknown in more than 90% of cases. In the pathogenesis of AD there are two principal hallmarks: neurofibrillary tangles (NFTs) and amyloid plaques. NFT are formed by the intracellular accumulation of phosphorylated tau protein and amyloid plaques, by extracellular accumulation of amyloid β peptides ([@B34]). The amyloid beta peptide is formed via cleavage of the amyloid precursor protein (APP). In the non-amyloidogenic pathway (normal state), APP is cleaved by α-secretase, to generate sAPP (soluble N- terminal fragment), which is neuroprotective as it is involved in the enhancement of synaptogenesis, neurite outgrowth, and neuronal survival. Conversely, in the disease state, APP is cleaved by β and γ secretase, resulting in insoluble beta amyloid peptide, which has high potential for assembly and formation of toxic aggregates ([@B27]).

Several mechanisms have been proposed to explain βA neurotoxicity, such as oxidative stress and loss of endogenous antioxidants ([@B7]; [@B3]; [@B33]); mitochondrial damage, depolarization, and mitochondrial permeability transition pore opening ([@B71], [@B70]; [@B2], [@B4]); destabilization of intracellular calcium homeostasis in neurons ([@B9]); glial cells ([@B1], [@B2]), and neuroinflammation ([@B67]).

Levels of melatonin and its precursors (serotonin and tryptophan) are significantly decreased in elderly AD individuals and are associated with the emergence of AD ([@B95]; [@B32]). A growing body of evidence supports the protective role of melatonin in several molecular mechanisms implicated in the development of AD.

Among these mechanisms, the most significant one is that melatonin prevents amyloid aggregation and overproduction. This neurohormone has a great affinity for Aβ peptide, preventing amyloid fibril formation ([@B63]), as determined by circular dichroism (CD) spectroscopy, electron microscopy, nuclear magnetic resonance (NMR) and electrospray ionization-mass spectrometry (ESI-MS). In particular, a hydrophobic interaction has been observed between melatonin and Aβ, specifically on the 29--40 residues of the Aβ segment ([@B85]). Additionally, melatonin has inhibitory effects on the formation of secondary β-sheet structures through the disruption of the histidine (His^+^) and aspartate (Asp^-^) salt bridges in Aβ peptide that promote fibril dissolution ([@B26]; [@B38]; [@B76]).

Melatonin presents a great capacity to regulate the synthesis and maturation of APP at different levels by: decreasing its mRNA encoding β-APP ([@B87]; [@B53]); blocking cAMP production, which is involved in activating the APP gene promoter, ([@B39]); and inactivating GSK-3, which promotes α-secretase mediated cleavage of APP, favoring the non-amyloidogenic pathway ([@B66]; [@B96]; [@B37]). *In vivo* studies with transgenic mice over-expressing APP (in 9--10 months they develop senile plaques) and fed with 0.5 mg/mL of melatonin in their drinking water (3 mL/day) found a reduction in important markers of the disease, including Aβ levels in the brain, and that some animals survived ([@B64]). The amount given to rodents are within the pharmacological dose and out of the range of the dose that can be achieved with moderate consumption of wine. Therefore it cannot be concluded that these effect will be observed in humans after wine intake. Further research is required to obtain the evidence at dietary doses.

Furthermore, melatonin exhibits a protective effect on the cholinergic system. In AD patients, a dramatic decrease of acetylcholine has been observed ([@B25]), which was related to a decrease in enzyme choline acetyltransferase (ChAT) activity and an increase in acetylcholinesterase (AChE) activity ([@B10]). Indeed, AChE inhibitors increase the synaptic levels of acetylcholine, which is why they are used as a treatment for mild to moderate AD. *In vivo* administration of melatonin in rats (50 mg/kg body weight) has led to significantly reduced AChE activity, with maintenance of calcium levels under conditions of oxidative stress ([@B63]). Regarding ChAT, melatonin increased its activity, after 4 months of melatonin administration in rats ([@B21]).

Finally, melatonin reduces Aβ-induced oxidative stress related to reactive oxygen species (ROS) and proinflamatory cytokines, such as IL6 and IL1-β in *in vivo* studies ([@B63]). As a result of these effects, melatonin protects brain neurons from damage and death by increasing viability in hippocampal neurons and glial cells following treatment with Aβ1--40, Aβ25--40, and Aβ1--28. Moreover, melatonin prevents the death of murine N2a neuroblastoma and PC12 cells by using Aβ25--35 ([@B77]; [@B40]).

There is scarce literature available in relation to the activity of other tryptophan metabolites, with indole 3-acetic acid and tryptophol being the only bioactive molecules reported so far. [@B72] proved the inhibitory effect of these indole derivatives on the amyloid fibrillation of hen egg-white lysozyme, which is another model for exploring the amyloidogenic mechanism.

Parkinson's Disease
===================

Parkinson's disease is the second most common neurodegenerative disorder. Its diagnosis is based on motor abnormalities, such as resting tremor, bradykinesia, and rigidity ([@B19]). Indeed, patients present other non-motor symptoms, such as depression, anxiety, and sleep disorders ([@B44]). Only 10% of patients have a genetic basis, with 90% being considered sporadic cases. PD is characterized by the degeneration of the subcortical structure of the brain. Specifically, there are significant losses of dopaminergic neurons in the substantia nigra pars compacta (SNpc; [@B24]), although other cell populations are also susceptible to the neurodegeneration process.

α-Synuclein (αS) is a 140 amino acid and a highly abundant neuronal protein. It is found as a soluble cytoplasmatic protein associated with synaptic vesicles ([@B42]). It is thought that it plays a role in neurotransmission and cognitive function. Although its physiological function is uncertain, the pathology is associated with the accumulation of αS aggregates, which are the main component of Lewy bodies (LBs; [@B88]). LBs are spherical inclusions formed by αS aggregate (99%) and other proteins.

Despite the main risk factor being aging, other possible risk factors include mutation in the SNCA (alpha-synuclein gene) and exposure to environmental toxins. The latter are also linked to metabolic abnormalities involving neurotransmitter systems (dopamine, serotonin, GABA, and glutamate), fatty acids, such as arachidonic acid-cascade, oxidative stress and mitochondrial function ([@B36]; [@B80]; [@B47]; [@B55]).

Furthermore, several studies suggest that αS oligomers and protofibrils are an important factor in neurotoxicity in PD. αS protofibrils cause membrane permeabilization, which alters cellular homeostasis and may activate an apoptotic process ([@B92]). Indeed, there is evidence to support the capacity of αS to inhibit proteosomal activity, which would prevent elimination of misfolded proteins ([@B29]).

Substantial evidence also suggests that a significant factor in dopaminergic neuronal loss in the PD brain are ROS, which result from dopamine metabolism, low glutathione concentration and high levels of iron and calcium in the SNpc ([@B45]). Additionally, the brain contains high concentrations of polyunsaturated fatty acids, which, under oxidative stress, result in lipid peroxidation and generation of toxic products ([@B58]).

No treatment is currently available for the prevention or cure of PD. However, a combination of L-DOPA and antioxidants has been recommended to reduce the rate of progression of the disease, due to the decrease in dopamine levels and significant increase of oxidative stress commonly concomitant to this type of disorder ([@B97]).

Concerning the role of melatonin in PD, several works have reported different mechanisms of action. [@B56] demonstrated that melatonin attenuates arsenite-induced apoptosis by reducing aggregated αS levels in rat brains, by means of Western blot analysis. Additionally, [@B41] showed that melatonin inhibits αS assembly, using immunostaining in rat pheochromocytoma cells.

It is also important to highlight that melatonin dose-dependently inhibits all steps of the αS assembly process. [@B74] observed a reduction in the number of fibrils and the corresponding increase of the number of short fibrils and amorphous aggregates (25--250 μM) using electron microscopy and thioflavin S experiments. Indeed, melatonin presents a significant destabilization effect (also dose-dependently), suggesting a decrease in beta-sheet levels. In the same study, the authors performed experiments with primary cultures of mesencephalon and neostriatum with MTT: (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) a colorimetric assay for assessing cell metabolic activity. The results showed that melatonin reduced the toxic effects of αS after pretreatment (2--6 days) with an increase in cell viability of between 56 and 97%.

In addition to this, it is well known that melatonin exhibits antioxidant properties ([@B81]; [@B52]). Cellular injury cause by αS-mediated perturbation of cellular redox reactions is an important mechanism proposed for PD ([@B28]). Melatonin has been suggested as a potential therapeutic agent in diseases where oxidative stress is thought to be a major pathogenic factor. [@B65] observed that this hormone was an effective free radical scavenger and that it prevented apoptosis in neuronal cells. Moreover, *in vitro* studies on MPTD-induced (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) PD in mice have shown that melatonin protects against excitotoxicity by reducing the autoxidation of dopamine. The administration of melatonin leads to normalization of complex I activity and oxidative status in mitochondria ([@B20]).

In conclusion, and based on the preceding evidence, we should consider that melatonin presents strong inhibitory effects on protofibril formation and peptide oligomerization.

Author Contributions
====================

RH-O and AC Literature search and first draft. AT, MG-P, and AM thorough revision and discussion and final document.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding**. This work was supported by the Ministry of Economy and Competitiveness, Spain (grant no. AGL2013-47300-C1 and AGL2013-47300-C3).

We acknowledge the Universidad de Sevilla for the contracts of AC and RH-O.

[^1]: Edited by: *Enrica Pessione, University of Turin, Italy*

[^2]: Reviewed by: *Robin Anderson, United States Department of Agriculture/Agricultural Research Service, USA; Paul Richard Himes, University of Louisville, USA*

[^3]: This article was submitted to Systems Microbiology, a section of the journal Frontiers in Microbiology
